NYSE:OPK
Opko Health Inc Stock News
$1.37
-0.0400 (-2.84%)
At Close: May 31, 2024
Pfizer - OPKO Health''s Growth Hormone Deficiency Candidate Receives FDA Response Letter
10:49am, Monday, 24'th Jan 2022 Benzinga
The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE ) and OPKO Health Inc''s (NASDAQ: OPK ) somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for pediatric growth hormone deficiency (GHD). Pfizer is evaluating the FDA''s comments. Earlier this week, Japan''s Ministry of Health, Labour, and Welfare
Pfizer, Opko Shares Fall After FDA Declines to Approve Somatrogon
07:27am, Monday, 24'th Jan 2022
Pfizer said it is evaluating the FDA's comments and will work with the agency "to determine an appropriate path forward."
OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment
02:16pm, Friday, 21'st Jan 2022 Zacks Investment Research
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment
10:49am, Friday, 21'st Jan 2022
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition
02:39pm, Tuesday, 18'th Jan 2022 Benzinga
Sema4 Holdings Corp (NASDAQ: SMFR ) has agreed to acquire OPKO Health Inc''s (NASDAQ: OPK ) wholly-owned subsidiary, GeneDx Inc , for approximately $623 million. Sema4 will acquire GeneDx for an upfront payment of $150 million in cash plus 80 million shares in Sema4, with up to an additional $150 million revenue-based milestones over the next two years. Together, Sema4 and GeneDx will be one of the largest providers of genomic clinical Full story available on Benzinga.com
Sema4 agrees to acquire OPKO Health''s GeneDx in ~$623M deal
02:25pm, Tuesday, 18'th Jan 2022 Seeking Alpha
Sema4 (SMFR) has agreed to acquire OPKO Health''s (OPK) wholly-owned subsidiary, GeneDx.Sema4 will make an upfront cash payment of $150M plus 80M in Sema4 shares
Stock Market News for Today, January 18th, 2022
02:09pm, Tuesday, 18'th Jan 2022 PennyStocks
What to watch with penny stocks today
The post Stock Market News for Today, January 18th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference
09:05pm, Wednesday, 05'th Jan 2022 Kwhen Finance
Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out
04:30pm, Sunday, 02'nd Jan 2022 PennyStocks
Add these three penny stocks to your January 2022 watchlist
The post Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out appeared first on Penny Stocks to Buy, Picks, News and Informatio
Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out
11:30am, Sunday, 02'nd Jan 2022
Add these three penny stocks to your January 2022 watchlist The post Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out appeared first on Penny Stocks to Buy, Picks, News and Informatio
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
07:40pm, Friday, 31'st Dec 2021 Benzinga
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entit
OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients
04:07pm, Monday, 27'th Dec 2021 Zacks Investment Research
Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.
OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients
12:14pm, Monday, 27'th Dec 2021
Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.
Hot Penny Stocks to Buy As 2021 Ends? 3 to Take a Look at Now
09:39pm, Thursday, 23'rd Dec 2021 PennyStocks
Check these three penny stocks out as 2021 comes to an end
The post Hot Penny Stocks to Buy As 2021 Ends? 3 to Take a Look at Now appeared first on Penny Stocks to Buy, Picks, News and Information |
Opko Health Posts Data From COVID-19 Trial With Its Kidney Disease Treatment
06:56pm, Thursday, 23'rd Dec 2021 Benzinga
OPKO Health Inc (NASDAQ: OPK ) has announced preliminary topline results from its Phase 2 trial with Rayaldee to treat mild-to-moderate COVID-19. This study builds on increasing medical evidence that vitamin D repletion therapy can mitigate the severity of upper respiratory tract infections and accelerate recovery from COVID-19. By Day 7, mean serum 25D levels increased with Rayaldee treatment to Full story available on Benzinga.com
